These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16849622)

  • 1. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin.
    LaFleur J; Thompson CJ; Joish VN; Charland SL; Oderda GM; Brixner DI
    Ann Pharmacother; 2006; 40(7-8):1274-9. PubMed ID: 16849622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
    Hussein MA; Chapman RH; Benner JS; Tang SS; Solomon HA; Joyce A; Foody JM
    Am J Cardiovasc Drugs; 2010; 10(3):193-202. PubMed ID: 20387911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence.
    Balu S; Simko RJ; Quimbo RM; Cziraky MJ
    Curr Med Res Opin; 2009 Nov; 25(11):2765-75. PubMed ID: 19785511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy.
    Patel BV; Remigio-Baker RA; Thiebaud P; Preblick R; Plauschinat C
    BMC Fam Pract; 2008 Nov; 9():61. PubMed ID: 18990240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
    Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    Rubenfire M;
    Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study.
    Ye X; Gross CR; Schommer J; Cline R; St Peter WL
    Clin Ther; 2007 Dec; 29(12):2748-57. PubMed ID: 18201593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims.
    McHorney CA; Victor Spain C; Alexander CM; Simmons J
    Clin Ther; 2009 Nov; 31(11):2584-607. PubMed ID: 20110004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of medication burden on persistent use of lipid-lowering drugs among patients with hypertension.
    Robertson TA; Cooke CE; Wang J; Shaya FT; Lee HY
    Am J Manag Care; 2008 Nov; 14(11):710-6. PubMed ID: 18999905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
    Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
    Vo AN; Kashyap ML
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1303-10. PubMed ID: 19018682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease.
    Hiatt WR; Hirsch AT; Creager MA; Rajagopalan S; Mohler ER; Ballantyne CM; Regensteiner JG; Treat-Jacobson D; Dale RA; Rooke T
    Vasc Med; 2010 Jun; 15(3):171-9. PubMed ID: 20212073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
    Bays HE; Maccubbin D; Meehan AG; Kuznetsova O; Mitchel YB; Paolini JF
    Clin Ther; 2009 Jan; 31(1):115-22. PubMed ID: 19243712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release niacin/lovastatin: the first combination product for dyslipidemia.
    Bays HE
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):485-501. PubMed ID: 15225109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice.
    Kamal-Bahl SJ; Burke TA; Watson DJ; Wentworth CE
    Curr Med Res Opin; 2008 Jun; 24(6):1817-21. PubMed ID: 18485268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
    Chodick G; Shalev V; Gerber Y; Heymann AD; Silber H; Simah V; Kokia E
    Clin Ther; 2008 Nov; 30(11):2167-79. PubMed ID: 19108805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.